FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
CO16 | The predictive value of high-sensitivity C-reactive protein for assessing thrombosis risk in non-small cell lung cancer P. Gomez-Rosas1,2, M. Marchetti1,3, L. Russo1, C.J. Tartari1, S. Bolognini1, C. Ticozzi1, F. Schieppati1, A. D’Alessio4, R. Labianca5, A. Falanga1,3 All on behalf of the Hypercan Investigators | 1Hospital Papa Giovanni XXIII, Bergamo, Italy; 2Cardiovascular Research Institute Maastricht, CARIM, Maastricht University, Maastricht, the Netherlands; 3School of Medicine and Surgery, University of Milan Bicocca, Italy; 4University Vita-Salute San Raffaele, Milan, Italy; 5Fondazione ARTET Onlus, Bergamo, Italy
636PDF: 16 -
PO42 | DIFFERENTIAL EXPRESSION OF HEMOSTATIC BIOMARKERS ACROSS CANCER TYPE AND DISEASE STAGE: A PROSPECTIVE ANALYSIS OF 4,292 PATIENTS FROM THE HYPERCAN STUDY P. Gómez-Rosas1|2|, D. Romeo1, S. Bolognini1, C. Ticozzi1, F. Schieppati1, A. D’Alessio4, R. Labianca4, A. Falanga1|5|6, M. Marchetti1|5|6 | 1Hospital Papa Giovanni XXIII, Bergamo, Italy; 2Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; 3Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; 4Fondazione ARTET Onlus, Bergamo, Italy; 5ERN EuroBloodNet; 6School of Medicine and Surgery, University of Milan Bicocca, Italy; *On Behalf Of The Hypercan Investigators
508PDF: 110 -
CO082 | IN SILICO ANALYSIS THROUGH A NEW-GENERATED FACTOR VIII MODEL SUPPORTS TOLERANCE OF B DOMAIN TO MULTIPLE AMINO ACID SUBSTITUTIONS, LIMITING THE LOCAL IMPACT OF MISSENSE VARIANTS A. Branchini1, M.F. Testa1, M. Pinotti1, R. De Cristofaro2|3 | 1Department of Life Sciences and Biotechnology, University of Ferrara, Italy; 2Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Roma, Italy; 3Center for Hemorrhagic and Thrombotic Diseases, Foundation University Hospital “A. Gemelli” IRCCS, Roma, Italy
23PDF: 10 -
PO116 | MONOCENTRIC EXPERIENCE OF DOACS REVERSAL MANAGEMENT AT L SACCO HOSPITAL, MILAN: A REAL-WORLD RETROSPECTIVE STUDY A. Veltroni, C. Sitzia, O. Di Bartolo, IM Burgo, MC. Carraro, S. Crivelli, C. Masseroni, GB. Inghilleri | Medicina Trasfusionale, Ospedale L. Sacco, Milano, Italy
19PDF: 8 -
CO010 | MAPPING HEMOSTATIC BIOMARKER EXPRESSION ACROSS CANCER TYPES AND STAGES WITHIN THE HYPERCAN COHORT P. Gómez-Rosas1|2, D. Romeo1, S. Bolognini1, C. Ticozzi1, F. Schieppati1|4|5, A. D’Alessio3, R. Labianca3, L. Barcella1|4|5, A. Falanga3|5, M. Marchetti1|4|5 | 1Hospital Papa Giovanni XXIII, Bergamo, Italy; 2Hospital de Oncología, Unidad Médica de Alta Especialidad (UMAE), Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Ciudad de México, México; 3Fondazione ARTET Onlus, Bergamo, Italy; 4ERN EuroBloodNet; 5School of Medicine and Surgery, University of Milan Bicocca, Italy. On behalf of the HYPERCAN Investigators
36PDF: 9 -
CO-05 | IN SILICO ANALYSIS THROUGH A NEWLY GENERATED FACTOR VIII MODEL SUPPORTS TOLERANCE OF B DOMAIN TO MULTIPLE AMINO ACID SUBSTITUTIONS LIMITING THE LOCAL IMPACT OF MISSENSE VARIANTS A. Branchini1, M.F. Testa1, M. Pinotti1, R. De Cristofaro2|3 | 1Department of Life Sciences and Biotechnology, University of Ferrara, Italy; 2Department of Translational Medicine and Surgery, Catholic University of the Sacred Heart, Roma, Italy; 3Center for Hemorrhagic and Thrombotic Diseases, Foundation University Hospital “A. Gemelli” IRCCS, Roma, Italy
88PDF: 15 -
PO44 | PREDICTORS OF ONE-YEAR MORTALITY IN NEWLY DIAGNOSED METASTATIC BREAST CANCER: THE PROGNOSTIC ROLE OF HEMOSTATIC BIOMARKERS AND EARLY THROMBOEMBOLISM M. Marchetti1|2|3, P. Gomez-Rosas1|4|5, S. Bolognini1, C. Ticozzi1, D. Romeo1, F. Schieppati1|3, L. Barcella1|3, F. Petrelli6, A. D'Alessio7, R. Labianca7, A. Falanga1|2|3 | 1Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy; 2School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy; 3ERN EuroBloodNet; 4Department of Biochemistry, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands; 5Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; 6Oncology Unit, Hospital Treviglio-Caravaggio, Treviglio, Italy; 7Fondazione ARTET Onlus, Bergamo, Italy; *On behalf of the Hypercan Investigators
473PDF: 107
1 - 9 of 9 items
